Executing A Complex Global Breast Cancer Trial In A Rapidly Evolving Treatment Landscape

Running a large, global breast cancer trial while treatment standards keep shifting is one of the toughest challenges in oncology research today. This case study follows a mid-sized biotech company developing a combination therapy for metastatic breast cancer, a fast-moving and highly competitive space. With roughly 140 sites across 16 countries, an already-approved base therapy that could complicate enrollment, strict contractual requirements, and a first-time regulatory submission through Europe's Clinical Trials Information System (CTIS), the sponsor needed a study team that could move fast without cutting corners on quality.

By running startup activities in parallel, tapping into strong relationships with high-performing oncology sites, and providing hands-on regulatory guidance, the study activated its first site in six weeks and enrolled its first patient just one day after treatment arrived on-site. Enrollment goals were met or exceeded across every cohort, and the study stayed inspection-ready even as new cohorts and combination regimens were added along the way. For sponsors navigating oncology trials in therapeutic areas where the standard of care can change mid-study, this case offers a practical look at how coordinated startup planning, experienced site networks, and adaptive protocol management can keep a complex global trial on track.